Replies to post #398215 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Thanks for that repost, sokol. Seems many here need to be reminded of the factual data and how more advanced with AD, at baseline, the blarcamesine patients were than lecanemab patients.

A very glaring point made by the author seems to slide by the doubters...

"Perhaps the results of the ADCS were disappointing. This possibility is contradicted by a statistic the company did report: those who took Blarcamesine were 167% more likely to improve their ADCS-ADL score by 3.5 points than placebo."

[nidan7500]

sokol

It will also be interesting to see how the EU regulators may react to Lecanemab given the failure of EU approval of Aduhelm. The EU said in its refusal to approve Adu, along with Adu’s side effects, noted this: “The European Medicines Agency noted that although Aduhelm reduces amyloid beta in the brain, the link between this effect and clinical improvement had not been established.” See: https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-refusal-marketing-authorisation-aduhelm-aducanumab_en.pdf

How many times does the Amyloid thesis (AD treatment) have to produce inconclusive or failed results before FDA declares it a missed approach and ultimately grounds the effort for good?

[sab63090]

Sokol:

Thanks, but tough for me to completely follow! I think I get the gist of it.

[powerwalker]

Many thanks to sokol, Mayo, and boi for their insights today.

As an aside: Knowing the headwinds Anavex would face with its revolutionary drug(s), Missling never claimed the Company/he would be transparent with results. This may have been too subtle for some, though he warned us when he stated (paraphrasing):

When you know what we did and why we did it, you will understand.

[plexrec]

sokol--thanks for this outstanding (well written) easy to understand post !! Kudo's !!!!!